British-based GW Pharmaceuticals announced positive Phase 3 study results of its drug Epidiolex for two treatment-resistant forms of epilepsy, at the 70th Annual Meeting of the American Epilepsy Society in Houston.
Epidiolex is an oral formulation of cannabidiol (or CBD), one of 500 compounds found in cannabis. Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does not have a psychoactive component and does not produce a “high”.
The results of the randomized, double-blind, placebo-controlled trials, suggest CBD may help reduce the frequency of seizures in children and adults with Dravet syndrome, and Lennox-Gastaut syndrome (LGS). Dravet and LGS are diagnosed early in childhood and are two of the most difficult forms of epilepsy to treat, with seizures often persisting for many years.
“For many children with treatment-resistant Dravet syndrome, Lennox-Gastaut syndrome and other epilepsies, CBD appears to be an effective- sometimes extremely effective – treatment that is safe and well-tolerated overall,” said study author Elizabeth Thiele,